Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing therapies for autoimmune diseases with significant unmet medical needs. The company has introduced LUPKYNIS® (voclosporin), the first FDA-approved oral treatment for adult lupus nephritis, and is advancing AUR200, a dual inhibitor targeting BAFF and APRIL for broader autoimmune disease treatments. Aurinia's focus on innovative drug development positions it as a leader in addressing complex immunological conditions.
Immunology Sales Specialist at Aurinia in Los Angeles, California, with a focus on selling approved therapy LUPKYNISTM for lupus nephritis. The role involves building business plans, providing clinical knowledge, and communicating with medical professionals.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing therapies for autoimmune diseases with significant unmet medical needs. The company has introduced LUPKYNIS® (voclosporin), the first FDA-approved oral treatment for adult lupus nephritis, and is advancing AUR200, a dual inhibitor targeting BAFF and APRIL for broader autoimmune disease treatments. Aurinia's focus on innovative drug development positions it as a leader in addressing complex immunological conditions.
Aurinia Pharmaceuticals Inc.